Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Harbour Biomed to Start US Trials of Novel B7H7 Immunoncology Asset

publication date: Jan 13, 2023

Harbour Biomed was cleared to start US Phase I trial of its novel, fully human mAb targeting B7H7 in patients with advanced solid tumors. The company points out that B7H7 is part of the B7 family, which has provided many successful immunoncology drugs, including PD-L1 and CTLA-4 drugs. Harbour says the candidate does not overlap with PD-L1 expression in multiple tumor types, implying it targets a different immune evasion pathway than PD-L1, which could benefit PD-L1 negative/refractory patients. Harbour is headquartered in Cambridge, MA, with drug discovery operations in Rotterdam and an R&D lab in Suzhou. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here